Body Mass Index Is Not Associated with Treatment Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Korean Data.
10.4048/jbc.2012.15.4.427
- Author:
Kyung Hun LEE
1
;
Bhumsuk KEAM
;
Seock Ah IM
;
Tae Yong KIM
;
Sae Won HAN
;
Do Youn OH
;
Jee Hyun KIM
;
Se Hoon LEE
;
Wonshik HAN
;
Dong Wan KIM
;
Tae You KIM
;
In Ae PARK
;
Dong Young NOH
;
Dae Seog HEO
;
Yung Jue BANG
Author Information
1. Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. moisa@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Breast neoplasms;
Neoadjuvant therapy;
Obesity;
Prognosis
- MeSH:
Body Mass Index;
Breast;
Breast Neoplasms;
Humans;
Neoadjuvant Therapy;
Obesity;
Overweight;
Prognosis
- From:Journal of Breast Cancer
2012;15(4):427-433
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The effects of body mass index on pathologic complete response and survival have not been reported in Korean patients with breast cancer. The purpose of this study was to evaluate the predictive or prognostic value of obesity in breast cancer receiving neoadjuvant chemotherapy. METHODS: A total of 438 stage II or III breast cancer patients treated with neoadjuvant chemotherapy were enrolled and analyzed retrospectively. RESULTS: In the study, 319 patients (72.8%) were normal weight, 100 patients (22.8%) were overweight, and 19 patients (4.3%) were obese. Baseline clinicopathologic characteristics were not different among the groups, except for age. There were no differences in pathologic complete response rate between the groups (9.7% in normal weight, 10.0% in overweight, 5.3% in obese; p=0.804). Neither overweight nor obese patients showed a significant difference in relapse-free survival compared to normal weight patients (p=0.523 and p=0.931, respectively). Also, no significant difference in overall survival (p=0.520 and p=0.864, respectively) was observed. CONCLUSION: Obesity or higher body mass index was not significantly associated with pathologic complete response and survival in Korean patients with breast cancer who received neoadjuvant chemotherapy. Our results suggest that the prognostic impact of body mass index is different from that of Western patients.
